Ernexa Therapeutics Closes New Funding Round

Core Insights - Ernexa Therapeutics is advancing its strategic focus on innovative cell therapies for cancer and autoimmune diseases, particularly ovarian cancer [1][2][3] - The company has entered into a securities purchase agreement for a private placement of approximately 69.3 million shares at a price of $0.1046 per share, totaling around $7.25 million, pending stockholder approval [1][2] - The first closing of this transaction occurred on April 2, 2025, raising approximately $1.1 million from the issuance of about 10.4 million shares [2] Company Overview - Ernexa Therapeutics specializes in developing cell therapies targeting advanced solid tumors and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) to create allogeneic synthetic mesenchymal stem cells (iMSCs) [4] - The company is currently focused on two preclinical cell therapy products: ERNA-101, aimed at treating ovarian cancer, and ERNA-102, designed to address inflammation in autoimmune diseases [5] Recent Developments - The recent fundraising follows a previous private investment in public equity (PIPE) round in 2024, which secured $5 million in financing [3] - Ernexa has undergone a rebranding to reflect its new strategic direction, emphasizing its commitment to advancing therapeutic innovation [2][3]